The Excedr Blog
Enhance your lab operations and funding strategies with actionable advice on equipment leasing, financing, procurement, and life sciences industry trends.
Electra Therapeutics: Pioneering SIRP-Targeted Therapy for sHLH
Electra Therapeutics: First-in-class SIRP-targeted therapy for sHLH with ELA026—Excedr covers this major biotech funding round. Explore data and pipeline.
October 2025
NewLimit: Using Epigenetic Reprogramming to Reverse Cellular Aging
NewLimit raises $45M to advance epigenetic reprogramming therapies targeting cellular aging—Excedr covers this major biotech funding round.
October 2025
Pelage Pharmaceuticals: Pioneering Stem Cell Therapy for Hair Loss
Pelage Pharmaceuticals raises $120M Series B for PP405 stem cell therapy in hair loss—Excedr covers this major biotech funding round.
October 2025
Peptilogics: Using AI-Powered Peptides to Combat Prosthetic Joint Infections
Peptilogics raises $78M to develop AI-designed peptides for joint infections—Excedr covers this major biotech funding round.
October 2025
Weave Bio: AI-Powered Regulatory Automation for Drug Development
Weave Bio’s $20M Series A accelerates AI automation in drug regulatory workflows—Excedr covers this major biotech funding round.
October 2025
Exactics: Building a Universal Platform for Rapid Infectious Disease Testing
Exactics pioneers rapid, at-home infectious disease tests with its adaptable Proteus+ platform—Excedr covers this major biotech funding round.
October 2025